FDA Recalls Boston Scientific Heart Devices

• Affected devices include Accolade, Essentio, Proponent, Altrua 2, Valitude and Visionist pacemakers, with 4 deaths and 2,557 serious injuries reported as of March 18, 2026
• The software update (Brady SMR6) is intended to fix problems caused by an earlier Boston Scientific update; the FDA warns continued use without correction could lead to serious injury or death
• Higher-risk patients who depend on the device and have limited battery life remaining should receive prompt follow-up, while routine follow-up is recommended for other patients

Summary: FDA Recalls Boston Scientific Heart Devices

The U.S. Food and Drug Administration has classified Boston Scientific's recall of multiple cardiac devices as a Class I recall—its most serious category—due to risks of serious injury or death.

Key Details

Affected Products: The recall covers six pacemaker models including Accolade, Essentio, Proponent, Altrua 2, Valitude, and Visionist pacemakers, as well as cardiac resynchronization therapy pacemakers.

Scope: As of March 18, 2026, Boston Scientific reported 4 deaths and 2,557 serious injuries linked to the device issues.

Corrective Action: The recall does not require device removal from patients or withdrawal from sale. Instead, physicians must update device software to Brady SMR6 during in-person clinic visits. The FDA indicated this software fix addresses problems caused by an earlier Boston Scientific update. The company is also developing an additional update to resolve a battery issue.

Patient Risk Categories: High-risk patients—including those device-dependent with limited battery life—require prompt follow-up appointments. Other patients can schedule routine follow-ups.

Market Implications

This Class I recall represents significant reputational and potential financial exposure for Boston Scientific (NYSE: BSX), a major player in the cardiovascular device sector. With thousands of serious injuries reported, the company faces potential litigation risks and regulatory scrutiny. The recall affects multiple flagship pacemaker products, which could impact market share and physician confidence in Boston Scientific devices. Investors should monitor any financial guidance updates and competitive positioning changes in the cardiac rhythm management market.

The recall underscores ongoing quality control challenges in the medical device industry and may prompt increased FDA oversight across the sector.